JANUARY 14, 2000 • HOUSTON VOICE
Youth takes on school officials to form student-led gay group
>■ Continued from Page 1
"I guess you could say I'm an 'in your face' kind of guy," he
says during an interview last week at LSU in Baton Rouge,
where he takes several hours of classes after leaving McKinley
High School "But hey, I'm gay, I'm queer, I'm out, I'm proud—
have I missed anything?" He grins broadly. "Could you tell?"
Could it be by the rainbow rings he wears around his neck7
Or the rainbow tag pinned to a shoulder strap on his backpack? Or the rainbow flag on the back of his mom's car?
Perhaps another telltale sign is the way he eagerly whips
out his wallet and pulls out two photographs of his boyfriend,
who attends another Baton Rouge high school.
For a moment, Pfeiffer's face clouds. "He has a hard time
sometimes," he said of his boyfriend. "He's taunted and
teased at school, but he says it's okay, that it's become 'normal'
VIRAMUNE (nevirapine) Tablets
VIRAMUNE (nevirapine) Oral Suspension
for him. That's disgusting. I wish 1 could do more to help
"Do more" doesn't adequately describe what Marty Pfeiffer
is doing—for himself, his boyfriend, and countless other gay
teens in Baton Rouge.
Pfeiffer has taken on the East Baton Rouge-Parish School
Board, McKinley High where he wants to start a Gay-Straight
Alliance for gay and gay-supportive students, and homo-
phobes who have unsuccessfully tried to skewer him and his
sexual orientation on radio programs—all at great risk for
being so public at a time when fanatics think nothing of sending hate mail, or worse.
"Yes, there are consequences for my actions and for being so
out, but the benefits far outweigh any negative consequences," Pfeiffer said. "People have to know it's okay to be
gay, to be out, to be themselves, and they don't have to take the
Table 1 wnuWLns Die muted laboratory abnormalities occurring in pediatric patents <" Trial Bl B82 and m Wow-up
Tape I Number ol PerJatnc Patents (%) wit) Matted Laboratory Abnonrames «i Tnas Bl 882 and Bl 89? Combined
St'/ERE ANU LIFE IHflfA'tNING 5KIN RiAC'IONS STEVENS jOHN'SUN iYNiJHGMf TOXIC EPIDERMAL
NECROLYSIS! INCLIJOING FATAL CASES HAVE OCCURRED IN PATIENTS TREATED WITH VIHAMUW~ (Sec
SEVERE AND LIFE THREATENING HEPATOTOXkCITY INCLUDING FATAL HEPATIC NECROSIS HAS OCCURRED
JH PATIENTS TREATED WITH VIRAMUNE- .See WARNINGS.
RESISTANT VIRUS EMERGES RAPIDLY AM UWEORMLY WHEN VIRAMUNE- IS ADMINISTERED AS
MONOTHERAPY THEREFORE. VIRAMUNE" SHOULD ALWAYS BE ADMINISTERED IN COMBINATION WITH
No (%) ol Pahents
Decreased Hg (<8.0 n/dL)
Decreased platelets (<SO.00O/mm')
Decreased neutiophus f<7S0/mm')
Increased AST (>250 UA)
Increased GGT (>450 UA|
increased total btkrubm (>2 5 mg/dl|
Increased aikahne phosphatase (-2- ULIM)
Increased amylase | >2« ULN)
ADVERSE KfilTIIOM: A**' The most freauenty reported adverse ev
S rented !0 VIRAMUNE* ihetapywi
Mteek ipmnml ttattpatam ttm
rfrtM YWAMUME- mmt ke *»m8iih >* palwtt levavlefkM I wm*J**mim), mi-quill k-ce-r
tfMkMl vyeeflMM sack as tenf. HMvMb, otI lesiets. op^mcMIs. nMMn, MHttt or |Mfll aches w lateral
iMim. [sm nEECMmoM. itiirHta
a* i l4-«atj lea* a MtrWi ef M Mtftt* |4 ikEutayt-f ■ pttttlrk iaftef*i|. tMdl Ml Mm Mm M rln
Mi mttwi < See DOSAGE AM lOMMSTRJirnN)
Sever, w m Wrmi—i NkakMidukj. wniin fate! WmeeeM MtaMB IhmiEWM ilnklm. m m »4kte-«
MiwtliiraMieMtt. piliikU RrW tWuMMimn M—, m mHiptlHi). *» nam M pMMet, Ira* ■*»
WAWF Stmt Owcan Mtjn m t» Itrtt tew -weta t. Urtvjw Mtnmwm i.cie-jiMiI *, im».
WWIIUNE- KiHiilliii OmU It mm\ttyM m patttwtt apthmtim ..iIwMe er mm AIT ■ AIT akeer
oaMfm MM M tlMtl M EJWJme nten «nVUJIUMP ShevU M piittawMhi kcHllMII it IHwt MaOM
^E»teMlM»!.IKtrMWIMMMM»NM«.NMll I ill I. MMtiMN MtM|Ml
tart M ewMki M mAMJNr UllflM. (See PRECAUTIONS MoflWPM Mr <WMtt: ADVERSE REACTIONS.
The r,-*y dawa* touctly of VIRAMUNE* is rash .with VIRAMUNE" annbutabte rash occurring m 11\ ot patents
-—- reganens m Phase ll/lll controlled stixkes Thirty seven percent ol tjatents Ireated with VIRAMUNE"
* compared with 20% of patents treated n control groups of ethetZDV.<Mi or ZDV alone I Tat* 2|
Severe or irle rweaiening rash occurred «i 16% o( VIRAMUNE" treated HMnts combated with 1 2% of patients
treated «i me control groups
Hashes are usuaky mild to moderate. macutopapuiar erythematous cutaneous eruptions with or without pruritus.
located on Itie Hunk, lace and extremities T^e rouotrty ot severe rashes occurred withm the firsl 28 days ot treat
nent 25*. ot the patients -with severe rashes required hospitalization and one patieM leouired surgical intervention
AN pahents recovered Overall. T\ of patents thscontimied VIRAMUNE* due to rash
aNe 2 Percemage ot Patents with Rashes n
■dun Controeed Trials
Rash events olal
Grades at* atcausany
in*** ' 'isn
events; all caosaMy
The Ovmn at dwiwl DemM from ant«-lrovwal theraoy rnay be h
antntrnwal therapy may contnue n develop onnfluntsOc inlections ana uotei corr
therefore should reman under close cimcai obsavanon by physicians expenenctd m the tteatment ot patients with
asfOC-M HW deeases
I ot an antiretroviral regimen, the complete product information for each ther
jf one 200 mg tablet darfy tor the first it toys fnloww) by one 200 mg tablet twice datty
11 Tna. ACTG 241 was designed to report Grade 3/4 (severe m ine-thr-aleiwg] events eicept tw several pre-specihed
events including rash lot when an grades are reported
Table 3 lists treat mem-related cHnca adverse events rhat occurred m itftents receiving VIRAMUNE* m ACTG 241 and
^ Trials Bl 1037 and Bl 1011
induction ol CYP3A By neyirapm* mav resull m lower p
r, admneaerefl drugs that ant nrtmsMsiv -Tiesaboiia-J By CVP3A fSe« a*iiCAL F*HAH*MC0irjGV> Thus 1 a
as been staUUM an a Aeag^ regetten to
«: VIRAMUNE' and nefoconsvole should not be
and neiocwwoie itsuted <i a sqnrkant reductinn m kMcccnanle pttsma caricefflrihons (See CLINICAL PHARMACOLOGY Drug interactions,
uVit CesncealMts: There are no clrad ijan
these drugs should not De jdm-iwered contoniitamty with VIRAMUNE'
anrltaM » prtjt«|it M«> ttw pl^^
fte test 6 weeks ot «iabon ol therapy Pttnts should be Etsttucted that 4 any rash cosirs dunrg ln« tvw>wee* lead-ei
pencd the VIRAMUNE' dose should not M escalated unW the-ash tsoiws Any pat-en: eiperenong seve-e ?sn «
a rash accompanied by const-tuhonai symptoms such as lever onsieting oral lesnns. conmndivitis. sMtkng muscle
ot (Ml aches, ot general matae should n-imedatety discontinue medcahon and consul a physcati
Palierfc should Wir^tucted that atwrmalirvw
recjafios have been reported w* V»UU*JME- Lr*t luncbon tests should be mon«ored es|»c^ during ihe hrg sii
months of Hwapy. VlfvVMJNE^ adrninrstrahon should be 'rtet■upted in pahents e*petetticmg moderakt ot severe kver
luncbsn lest ^wiiiawti. uM luer function tests return to tuselme values. VIRAMUNE- should be oemunetitfy avs
contimied i kver function atttormaltnes reciu upon -eadminfif ration Pahents should be -Tstrucied to consult their
physicians imnvsdufely should symptoms ot hepatite occut
Oral contraceptrws and other tiomwnal methods ot bwth control should not be used as a method of cortiwpbon m
women tatong ViiuVtwUNE" (See PRECAUTIONS drug Itmnaions)
i^ierrrs shaiid M irilormed that WRAM^
to others tntough se.ua! contact * wood contaminalion Ttxior^letmettectsotVtluuVILWE- afe.niuTownatttvshme
Trearmerrt with VIRAMUNE" has not Been shown to iedu« W .nooenct o<
ews snoun t» at>nMd to narian urioto «w
take VIRAMUNE' every day as prescribed Patients should not alter tie dose without
Tawe 3 Cottiparattve Incidence ol SHecied Drug Heiaied Events m Adult Controlled
Tral 811037and BMOIt
Grade 3/4 events
NumOe' ol patients
Overal ruotna ot related aoverss everts
AMerwiWiei: Table 4 summarizes matted OOo
Table 4: Percenaoe ot Adult Patients w
lory abnormal*** oecutritg ei Ihne contnsled studw
i Matted Laboraioty Abnormalities
AST 1.250 U/Lj
tt if rMlttjc Long-term canprngenaty studies ot
:urwit, m progiess m genet.: toiiccwjgy assays nevrac.ne shrowed no ftioerw ot mutagen* ot daaogenc actwfy
>■ a ladEry of ei »M and n nw attsays intsyjoVng
-; cow), mammalian ceJ gent mutation assays iCHO.HCPRTt cywgenepc assays using a Chants* hamstet ovary eel
d on AUC appron
wtinvendtd especialty duting Ihe tirsf so m.
iruvhit .uq ^vsfernff eiposure
Wiptwt|. -"egnancv Categor, C No DOservaWe leiatooemcity was detected m leproductive
tf 50% Ikgner based on AUC than that seen at the recommended human ckneal dose
tat no^rjbswivaoit eltect level dosages in tats and rabbits produced system*;
— '"% i-ghw. test«awely. than ttov
and I*?'! cnmroiuid-.; .^^ riprf,
Wtmatic elevations in GGT levels are more frequent in VIRAMUNE* recipients than in controls Because Ckmcal
« ol VIIUMUW' treatment , See WARNINGS,
" ■ ■ tM HI mm comr.on\ of
" IMMH 'u-i iHit beeih esLih!,s"ed
n antidote 'i- VIRAMUNE' ovetdosage Cases ol VlFtAMUNE* ovetdose at doses
■arginij fiom 800 to l8tM mtj per tliy ttir up to 15 ittys Maw been reporreej Pahents have eipenenced tNents TOucwig
— *ihgu*. ttvtt headache msomna. nuM "
is supsTjefl loiio" ng MeoM MM M Pi
HMRi MM EklikjMJU In
>MT% IMtenr PrekRvatvy irjsufs ffl^
wonten wt« were adtniHWed a swtte or* u^
intkate that nivirapfie readrly cmsses the placenta and is found m breast mtk Consistent with the i»a-T*T>*nilaon
by the US Public MeaBh Service Centers tot Disease Control and F^everihcn that HTV-intededitKithefsr^
iTtarts to M>d ttsfraii ptMatt
Peetewx bkc Safety wk assessed m mat 81852 m wheh pahenls were Mowed lor a mean uuraMn of 33 9 -norths
■'*ioe b"3-horrnsfoS3'fears rcluoviig wcj-ierm'on^-up ir?9oi these palieirtsji'rai Bl 992i The most TequemN
erceotion ot granutocytcmna when was more commoiiiy oKer^ in chrttten Serious adverse events were assessed
■ ACTG ?45 a double Wnd placebo controlled trial rfWfi>J*iNE- |n = 305) m wheh ptaUnc patents received
MnWabon treatment ■* vrtWIU*' m the; tie! two pahents were reported ID ewerenct SW-WVJilhnson svn-
liYtjnytafSieMfts-JDlmorVt^ Cases of aiietgic reaction irciuthng one case
ot anat>hyta«. «««a^-evortefl Tie eval^
f III I Boehringerlngelheiin
MlHiy Roxane Laboratories
GLSEN's Brenda Barron says only two school systems—in California
and Utah—have not allowed chapters of gay-straight alliances.
harassment, that they can fight back. I'm not afraid, no matter
what may happen. I'm never going back into the closet. Never."
A rough road to take
Pfeiffer's transformation to gay activist didn't occur without personal angst and pain.
Although he suspected he was gay for many years, it wasn't until he was a teenager that he came to grips with the reality. During middle school years—sixth through eighth
grades—he endured perpetual taunting and teasing.
"I was preppy in those days," he says. "I sensed I was different, and at that age 'different' is bad. The worst thing you
could assign to yourself was that you're gay.
"I was called 'fag' daily, teased, and picked on. Why?
Because I was quiet and kept to myself, and I didn't like girls."
Pfeiffer said his depression deepened. As he moved into
high school, rumors that he was gay persisted "and I was
making a real effort to hide it."
When his mother "had the big sex talk with me, I told her
I'd never have sex with a woman, so she knew something was
up." Sensing her son's growing despair, his mother got him
into therapy. By ninth grade, Pfeiffer said, he had had enough.
"1 here were a lot of things going on in the news, and 1 was
beginning to mourn the fact that I never had a childhood
because of the way other students treated me.
"One day, my mom and I were in Wal-Mart—I could show
you the exact spot—and she asked me what was wrong, why
1 was so quiet. So 1 jusl blurted it out. ... She said it wasn't a
complete surprise. I think she talked to my aunt, who's really
cool .. I know it wasn't easy for her, but my mother made if
very clear she loved me no matter what."
It was his mother who found a gay youth group at the
Baton Rouge lambda Center, and who continues to provide constant support.
"My father, well, that's a different story," Pfeiffer says quietly. I lis father believes homosexuality is wrong "so we don't
talk about it much." T'amily counseling has eased some of the
stress, he adds, "but it's still very hard."
Rebel with a cause
Pfeiffer began networking through Umbda, the Gay,
Lesbian and Straight Education Network, and the Internet,
and his transformation from timid closet-case to out-and-
proud gay activist continues.
"Being gay is not about sexual behavior, you know," he
says. "Why characterize someone thai way? People want
to reduce il to sex, but that's unfair. ... Everyone assumes
you're heterosexual, but how do you know that? How do
you know you're gay? You just know by the way you read
to people. Bui we receive signals and have internalized
messages society has sent us: Don't buck the system; don't